Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Rasagiline - Teva Pharmaceutical Industries

Drug Profile

Rasagiline - Teva Pharmaceutical Industries

Alternative Names: Agilect; AGN 1135; Azilect; Elbrus; Lu 00-773; Rasagiline mesilate; Rasagiline mesylate; TV-1030; TVP 101; TVP 1012

Latest Information Update: 04 Nov 2018

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Technion - Israel Institute of Technology
  • Developer Lundbeck A/S; Takeda; Teva Pharmaceutical Industries
  • Class Amines; Antiparkinsonians; Indans; Small molecules
  • Mechanism of Action Monoamine oxidase B inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Parkinson's disease
  • Discontinued Alzheimer's disease

Most Recent Events

  • 01 Nov 2018 Takeda plans a post-marketing surveillance study for Parkinson's disease in Japan (JapicCTI-184181)
  • 30 Oct 2018 Launched for Parkinson's disease in Japan (PO) (JapicCTI-184181))
  • 01 Mar 2018 Registered for Parkinson's disease in Japan (PO) (Takeda pipeline, May 2018)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top